BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 33909231)

  • 1. Concomitant inhibition of B7-H3 and PD-L1 expression by a novel and synthetic microRNA delivers potent antitumor activities in colorectal tumor models.
    Meng F; Chen Y; Yang M; Zhang H; Wang W
    Invest New Drugs; 2021 Oct; 39(5):1267-1274. PubMed ID: 33909231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 3. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-34a induces immunosuppression in colorectal carcinoma through modulating a SIRT1/NF-κB/B7-H3/TNF-α axis.
    Meng F; Yang M; Chen Y; Chen W; Wang W
    Cancer Immunol Immunother; 2021 Aug; 70(8):2247-2259. PubMed ID: 33492448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma.
    Lu Z; Zhao ZX; Cheng P; Huang F; Guan X; Zhang MG; Chen HP; Liu Z; Jiang Z; Zheng ZX; Zou SM; Wang XS
    Mod Pathol; 2020 Nov; 33(11):2330-2340. PubMed ID: 32514163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-H3, Negatively Regulated by miR-128, Promotes Colorectal Cancer Cell Proliferation and Migration.
    Hu X; Xu M; Hu Y; Li N; Zhou L
    Cell Biochem Biophys; 2021 Jun; 79(2):397-405. PubMed ID: 33743142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.
    Wu RY; Kong PF; Xia LP; Huang Y; Li ZL; Tang YY; Chen YH; Li X; Senthilkumar R; Zhang HL; Sun T; Xu XL; Yu Y; Mai J; Peng XD; Yang D; Zhou LH; Feng GK; Deng R; Zhu XF
    Clin Cancer Res; 2019 Jul; 25(14):4530-4541. PubMed ID: 30940655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of liver-targeted drugs on expression of immune-related proteins in hepatocellular carcinoma cells.
    Qiu MJ; He XX; Bi NR; Wang MM; Xiong ZF; Yang SL
    Clin Chim Acta; 2018 Oct; 485():103-105. PubMed ID: 29940148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
    Roshani Asl E; Rasmi Y; Baradaran B
    J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
    Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity.
    Nagase-Zembutsu A; Hirotani K; Yamato M; Yamaguchi J; Takata T; Yoshida M; Fukuchi K; Yazawa M; Takahashi S; Agatsuma T
    Cancer Sci; 2016 May; 107(5):674-81. PubMed ID: 26914241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
    Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
    Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA miR-29a Inhibits Colon Cancer Progression by Downregulating B7-H3 Expression: Potential Molecular Targets for Colon Cancer Therapy.
    Wang J; Chen X; Xie C; Sun M; Hu C; Zhang Z; Luan L; Zhou J; Zhou J; Zhu X; Ouyang J; Dong X; Li D; Zhang J; Zhao X
    Mol Biotechnol; 2021 Sep; 63(9):849-861. PubMed ID: 34100183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
    Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
    Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
    [No Abstract]   [Full Text] [Related]  

  • 15. Expression status of PD-L1 and B7-H3 in mesothelioma.
    Matsumura E; Kajino K; Abe M; Ohtsuji N; Saeki H; Hlaing MT; Hino O
    Pathol Int; 2020 Dec; 70(12):999-1008. PubMed ID: 33027549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
    Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
    J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum miR-1301-3p, miR-335-5p, miR-28-5p, and their target B7-H3 may serve as novel biomarkers for colorectal cancer.
    Wang L; Zhao Y; Xu M; Zhou F; Yan J
    J BUON; 2019; 24(3):1120-1127. PubMed ID: 31424670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
    Scribner JA; Brown JG; Son T; Chiechi M; Li P; Sharma S; Li H; De Costa A; Li Y; Chen Y; Easton A; Yee-Toy NC; Chen FZ; Gorlatov S; Barat B; Huang L; Wolff CR; Hooley J; Hotaling TE; Gaynutdinov T; Ciccarone V; Tamura J; Koenig S; Moore PA; Bonvini E; Loo D
    Mol Cancer Ther; 2020 Nov; 19(11):2235-2244. PubMed ID: 32967924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
    Tu J; Xu H; Ma L; Li C; Qin W; Chen X; Yi M; Sun L; Liu B; Yuan X
    Theranostics; 2022; 12(2):747-766. PubMed ID: 34976211
    [No Abstract]   [Full Text] [Related]  

  • 20. B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer.
    Zhang W; Acuna-Villaorduna A; Kuan K; Gupta S; Hu S; Ohaegbulam K; Albanese J; Kaumaya M; Levy R; Hwang RR; Zang X; Lin J; Liu Q; Maitra R; Goel S
    Clin Colorectal Cancer; 2021 Jun; 20(2):161-169. PubMed ID: 33745842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.